[go: up one dir, main page]

AR132415A1 - Radiopharmaceutical agents targeting extracellular HSP90 (eHSP90) and their use - Google Patents

Radiopharmaceutical agents targeting extracellular HSP90 (eHSP90) and their use

Info

Publication number
AR132415A1
AR132415A1 ARP240100928A ARP240100928A AR132415A1 AR 132415 A1 AR132415 A1 AR 132415A1 AR P240100928 A ARP240100928 A AR P240100928A AR P240100928 A ARP240100928 A AR P240100928A AR 132415 A1 AR132415 A1 AR 132415A1
Authority
AR
Argentina
Prior art keywords
ehsp90
agents targeting
radiopharmaceutical agents
targeting extracellular
extracellular hsp90
Prior art date
Application number
ARP240100928A
Other languages
Spanish (es)
Inventor
Christopher Paul Leamon
Hari Krishna R Santhapuram
Iontcho R Vlahov
Samuel Kunjunju Kutty
Stuart James Mahoney
Alexander James Nielsen
Original Assignee
Fusion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Pharmaceuticals Inc filed Critical Fusion Pharmaceuticals Inc
Publication of AR132415A1 publication Critical patent/AR132415A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo. Una composición farmacéutica que comprende un compuesto de acuerdo con cualquiera de las reivindicaciones 1 - 27 y un excipiente farmacéuticamente aceptable. Un compuesto de acuerdo con cualquiera de las reivindicaciones 1 - 27, o la composición farmacéutica de acuerdo con la reivindicación 28, para usar en un método para el tratamiento del cáncer.A compound of formula (1), or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising a compound according to any one of claims 1-27 and a pharmaceutically acceptable excipient. A compound according to any one of claims 1-27, or the pharmaceutical composition according to claim 28, for use in a method for the treatment of cancer.

ARP240100928A 2023-04-14 2024-04-12 Radiopharmaceutical agents targeting extracellular HSP90 (eHSP90) and their use AR132415A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363496233P 2023-04-14 2023-04-14

Publications (1)

Publication Number Publication Date
AR132415A1 true AR132415A1 (en) 2025-06-25

Family

ID=93058581

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100928A AR132415A1 (en) 2023-04-14 2024-04-12 Radiopharmaceutical agents targeting extracellular HSP90 (eHSP90) and their use

Country Status (3)

Country Link
AR (1) AR132415A1 (en)
TW (1) TW202446370A (en)
WO (1) WO2024212001A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
CN119236123A (en) * 2018-04-05 2025-01-03 融合制药公司 HSP90-targeted conjugates and their preparations
JP7753097B2 (en) * 2019-04-03 2025-10-14 フュージョン ファーマシューティカルズ インコーポレイテッド HSP90-binding conjugates and preparations thereof
WO2024044755A2 (en) * 2022-08-26 2024-02-29 Fusion Pharmaceuticals Inc. Extracellular hsp90 (ehsp90)-targeted radiopharmaceuticals and use thereof

Also Published As

Publication number Publication date
WO2024212001A1 (en) 2024-10-17
WO2024212001A9 (en) 2025-06-19
TW202446370A (en) 2024-12-01

Similar Documents

Publication Publication Date Title
UY38880A (en) BRD9 BIFUNCTIONAL DEGRADERS AND THEIR USE METHODS
MX2020009856A (en) RIMEGEPANT FOR CALCITONIN GENE-RELATED PEPTIDE (CGRP)-RELATED DISORDERS.
MX2021011606A (en) Compounds targeting prmt5.
MX2020009530A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors.
AR131639A1 (en) KIF18A INHIBITORS AND THEIR USES
GT200600163A (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION
CL2023003327A1 (en) Inhibitors of the menin-mll interaction
CO2022015428A2 (en) Deuterated oxophenylarsine compound and use thereof
AR130602A1 (en) TEAD INHIBITORS AND METHODS OF USE THEREOF
MX2020011367A (en) OXO-SUBSTITUTED COMPOUND.
CO2025016753A2 (en) gsk3α inhibitors and methods of their use
AR127165A1 (en) RESMETIROM TO REDUCE LIVER VOLUME
AR132415A1 (en) Radiopharmaceutical agents targeting extracellular HSP90 (eHSP90) and their use
AR134204A1 (en) NEW COMPOUNDS AS SODIUM CHANNEL MODULATORS AND THEIR USES
AR134453A1 (en) CBL-B INHIBITORS AND METHODS OF THEIR USE
AR131842A1 (en) METHODS FOR TREATING GLIOMAS
AR132166A1 (en) NLRP3 INFLAMMASOME INHIBITORS AND THEIR USES
AR132983A1 (en) KEAP1 INHIBITORS AND THEIR USES
CO2023017669A2 (en) Advantageous anti-hcv combination therapy
AR130303A1 (en) PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE
AR128100A1 (en) COMPOUNDS FOR THE TREATMENT OF HAIR LOSS
AR126393A1 (en) COMBINED THERAPY FOR THE TREATMENT OF LIVER DISEASES
CO2021002980A2 (en) Dendrimer formulations
AR129171A1 (en) HETEROAROMATIC COMPOUNDS
AR134491A1 (en) TYK2 INHIBITORS AND THEIR USES

Legal Events

Date Code Title Description
FB Suspension of granting procedure